Abstract
For prevention and early detection of dependence on hypnotics such as benzodiazepines (BZDs) or its agonists, a withdrawal symptom scale specialized for this kind of drug has long been sought. In this study, the benzodiazepine hypnotics withdrawal symptom scale (BHWSS) was developed using item response theory (IRT). This study enrolled 121 chronic insomnia patients (mean age 46.1 ± 15.6 years) who had been treated with hypnotics for 3 or more months. The patients were asked to fill a questionnaire that was developed by selecting questions from Benzodiazepine Withdrawal Symptom Questionnaire (BWSQ) and Clinical Institute Withdrawal Assessment for Benzodiazepines (CIWA-B) on the basis of the symptoms triggered by reduction or abrupt cessation of the intake of hypnotics. A factor analysis was performed to verify the assumption that the new scale had one dimension. We drew item response category characteristic curves, following the IRT. Besides statistical considerations, clinical implications were also incorporated to select the 12 items used to construct the BHWSS questionnaire. Using the analyses based on IRT, 6 items each were selected from BWSQ and CIWA-B. The cumulative proportion of contribution of the first factor, obtained by factor analysis, was found to be 0.36. Cronbach’s α coefficient and McDonald’s ω coefficient were calculated to be 0.86 and 0.87, respectively. The total score of 12 items increased monotonically with the increasing level of withdrawal symptoms. The BHWSS could potentially become a practical tool for estimating the degree of BZD withdrawal symptoms.
Similar content being viewed by others
References
American Academy of Sleep Medicine. International classification of sleep disorders, 3rd ed. Darien: American Academy of Sleep Medicine; 2014.
Ohayon MM, Partinen M. Insomnia and global sleep dissatisfaction in Finland. J Sleep Res. 2002;11:339–46.
Mellinger GD, Balter MB, Uhlenhuth EH. Insomnia and its treatment. Prevalence and correlates. Arch Gen Psychiatry. 1985;42:225–32.
Vgontzas AN, Liao D, Bixler EO, Chrousos GP, Vela-Bueno A. Insomnia with objective short sleep duration is associated with a high risk for hypertension. Sleep. 2009;32:491–7.
Staner L. Comorbidity of insomnia and depression. Sleep Med Rev. 2010;14:35–46.
Baglioni C, Battagliese G, Feige B, Spiegelhalder K, Nissen C, Voderholzer U, Lombardo C, Riemann D. Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies. J Affect Disord. 2011;135:10–9.
Smith MT, Perlis ML, Park A, Smith MS, Pennington J, Giles DE, Buysse DJ. Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia. Am J Psychiatry. 2002;159:5–11.
Okajima I, Komada Y, Inoue Y. A meta-analysis on the treatment effectiveness of cognitive behavioral therapy for primary insomnia. Sleep Biol Rhythms. 2011;9:24–34.
Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017;13:307–49.
Murakoshi A, Takaesu Y, Komada Y, Ishikawa J, Inoue Y. Prevalence and associated factors of hypnotics dependence among Japanese outpatients with psychiatric disorders. Psychiatry Res. 2015; 230:958–963.
Hallstron C. Benzodiazepine withdrawal phenomena. Int Pharmacopsychiatry. 1981;16:235–44.
Busto U, Sellers EM, Naranjo CA, Cappell H, Sanchez-Craig M, Sykora K. Withdrawal reaction after long-term therapeutic use of benzodiazepines. N Engl J Med. 1986;315:854–9.
Barker MJ, Greenwood KM, Jackson M, Crowe SF. Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs. 2004;18:37–48.
de las Cuevas C, Sanz E, de la Fuente J. Benzodiazepines: more “behavioural” addiction than dependence. Psychopharmacology. 2003;167:297–303.
Ashton H. Guidelines for the rational use of benzodiazepines. When and what to use. Drugs. 1994;48:25–40.
Bloom HG, Ahmed I, Alessi CA, Ancoli-Israel S, Buysse DJ, Kryger MH, Phillips BA, Thorpy MJ, Vitiello MV, Zee PC. Evidence-based recommendations for the assessment and management of sleep disorders in older persons. J Am Geriatr Soc. 2009;57:761–89.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. American Psychiatric Association, Arlington; 2013.
Lader M. Benzodiazepine harm: how can it be reduced? Br J Clin Pharmacol. 2014;77:295–301.
Paquin AM, Zimmerman K, Rudolph JL. Risk versus risk: a review of benzodiazepine reduction in older adults. Expert Opin Drug Saf. 2014;13:919–34.
Tyrer P, Murphy S, Riley P. The benzodiazepine withdrawal symptom questionnaire. J Affect Disord. 1990;19:53–61.
Busto UE, Sykora K, Sellers EM. A clinical scale to assess benzodiazepine withdrawal. J Clin Psychopharmacol. 1989;9:412–6.
Christine DeMars. Item response theory (understanding statistics). Oxford University Press, New York; 2010 ISBN-13:978-0195377033.
Lähteenmäki R, Puustinen J, Vahlberg T, Lyles A, Neuvonen PJ, Partinen M, Räihä I, Kivelä SL. Melatonin for sedative withdrawal in older patients with primary insomnia: a randomized double-blind placebo-controlled trial. Br J Clin Pharmacol. 2014;77:975–85.
Lichstein KL, Nau SD, Wilson NM, Aguillard RN, Lester KW, Bush AJ, McCrae CS. Psychological treatment of hypnotic-dependent insomnia in a primarily older adult sample. Behav Res Ther. 2013;51:787–96.
Roehrs TA1, Randall S, Harris E, Maan R, Roth T. Twelve months of nightly zolpidem does not lead to rebound insomnia or withdrawal symptoms: a prospective placebo-controlled study. J Psychopharmacol. 2012;26:1088–95.
Krystal AD1, Lankford A, Durrence HH, Ludington E, Jochelson P, Rogowski R, Roth T. Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia. Sleep. 2011;34:1433–42.
Wade AG, Ford I, Crawford G, McConnachie A, Nir T, Laudon M, Zisapel N. Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety. BMC Med. 2010;8:51. https://doi.org/10.1186/1741-7015-8-51.
Toyoda H. Item response theory—case example.In 項目反応理論[事例編]. 7th ed. Tokyo: Asakura Publishing Co., Ltd; 2014.
McDonald RP. Generalizability in factorable domains: “domain validity and generalizability" 1. Educ Psychol Meas. 1978;38:75–9.
Couvée JE1, Zitman FG. The Benzodiazepine Withdrawal Symptom Questionnaire: psychometric evaluation during a discontinuation program in depressed chronic benzodiazepine users in general practice. Addiction. 2002;97:337–45.
Tolbert D, Harris SI, Bekersky I, Lee D, Isojarvi J. Withdrawal-related adverse events from clinical trials of clobazam in Lennox–Gastaut syndrome. Epilepsy Behav. 2014;37:11–5.
Acknowledgements
For creating of the new scale reported in this study, we obtained permission from Peter Tyrer (BWSQ) and Edward M. Sellers (CIWA-B) to use the questionnaire scales. The authors would like to offer special thanks to Shyun Nakajima, staff of Teikyo University, and Moeko Ochi, staff of Soshin Mental Care Clinic for recruitment and collecting data. We would like to thank Editage (http://www.editage.jp) for English language editing.
Funding
This research is supported by the “Health and Labor Sciences Research Grants for Comprehensive Research on Persons with Disabilities” from Japan Agency for Medical Research and Development, AMED and Intramural Research Grant (29-1) for Neurological and Psychiatric Disorders of NCNP.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Takashi Kikuchi, a member of Translational Research Information Center, was consulted for statistical analysis but was not involved in writing the manuscript or collecting data. Other authors have no conflict of interest in this study.
Ethical approval
All the procedures undertaken to perform experiments involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all the participants included in this study.
Rights and permissions
About this article
Cite this article
Kobayashi, M., Okajima, I., Narisawa, H. et al. Development of a new benzodiazepine hypnotics withdrawal symptom scale. Sleep Biol. Rhythms 16, 263–271 (2018). https://doi.org/10.1007/s41105-018-0151-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s41105-018-0151-0